Concurrent Treatment of Osteoporosis for Prevention of Vertebral Fracture in Japan - Multi-center Randomized Trial with Arendoronate and alfa-calcidol -

Concurrent Treatment of Osteoporosis for Prevention of Vertebral Fracture in Japan - Multi-center Randomized Trial with Arendoronate and alfa-calcidol - - Japanese Osteoporosis Intervention Trial (JOINT) -02

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-C000000001

Enrollment

2140

Registered

2005-07-01

Start date

2003-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoporosis

Interventions

alendronate(2years) alendronate+active vitaminD3(2years)

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: osteoporosis, prevalent vertebral fracture number==70year women, possible to walk alone, risk foctor number of incident vertebral fracture=>1,possible to answer QOL questionnaire

Exclusion criteria

Exclusion criteria: Bone disease other than osteoporosis, having contraindication in using drugs, disfunction of communication of the intention, deformation of vertebra, hyperthyroidism, hyperparathyroidism, abnormal heart function, abnormal hepatic function, abnormal kidney function, taken bisphosponate within previous 6 months

Design outcomes

Primary

Measure	Time frame
Incident vertebral fracture rate	—

Secondary

Measure	Time frame
Period of incident vertebral fracture, non-vertebvral fracture rate, bone mineral density, QOL, Sreum vitamin D, safety	—

Countries

Japan

Contacts

Public ContactTatsuhiko Kuroda

Public health research foundation CSP-A-TOP

a-top@csp.or.jp03-5287-2633

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026